首页 > 用药指导 > 文章详情

Baricitinib(艾乐明)巴瑞替尼的用法用量及副作用

发布时间:2025-04-16 09:39:23 阅读:1346 来源:问药网
分享至

分享到微信朋友圈

×

打开微信,点击底部的“发现”,

使用“扫一扫”即可将网页分享至朋友圈。

巴瑞替尼片

巴瑞替尼片 生产厂家:印度纳科Natco制药有限公司 功能主治:JAK1/2抑制剂,用于多种炎症性疾病和自身免疫性疾病 用法用量:用法用量  1、类风湿性关节炎  OLUMIANT的推荐剂量为每日1次口服2mg,餐前餐后都可。  OLUMIANT可以单独使用,也可以与甲氨蝶呤或其他非生物dmard联合使用。  2、COVID-19(新冠病毒)  成人OLUMIANT的推荐剂量为每日一次口服4mg,餐前餐后都可,持续14天或直到出院,以先发生者为准。  3、斑秃  OLUMIANT的推荐剂量是2mg,每天一次口服,餐前餐后都可。  如果对治疗的反应不充分,增加到每天一次4mg。  对于几乎完全或完全的头皮脱发,睫毛或眉毛有或没有大量脱发的患者,考虑每天一次4mg治疗,伴餐前餐后都可。  一旦患者对4mg的治疗产生了充分的反应,将剂量减少到2mg,每天一次。  对于无法吞下整片药片的患者,可以考虑另一种给药方式:  1、口服分散  2、胃造口管(G管)  3、鼻胃管(NG管)或口胃管(OG管)
查看详情

Baricitinib(艾乐明)巴瑞替尼的用法用量及副作用,巴瑞替尼(Baricitinib)常见副作用有:1、严重感染,如肺炎、带状疱疹和尿路感染;2、死亡率,50岁以上及有心血管疾病的患者有更高的全因死亡率;3、恶性肿瘤和淋巴增生性疾病;4、重大心血管不良事件;5、血栓形成;6、会出现过敏反应;7、胃肠道穿孔;8、可能会对胎儿造成损害。

Baricitinib (trade name Olumiant) is a medication used for the treatment of rheumatoid arthritis, COVID-19, and alopecia areata. It belongs to a class of drugs known as Janus kinase inhibitors, which work by blocking specific enzymes that play a role in the inflammation process. Baricitinib has been approved by regulatory authorities in several countries and has been found to be effective in managing these conditions. However, it is important to understand its appropriate use, dosage, and potential side effects.

1. Baricitinib for Rheumatoid Arthritis:

Rheumatoid arthritis is a chronic autoimmune disease that causes joint inflammation and can lead to significant pain and disability. Baricitinib is indicated for the treatment of moderate to severe rheumatoid arthritis in adults who have not responded adequately to conventional disease-modifying antirheumatic drugs (DMARDs). The recommended dosage of baricitinib for rheumatoid arthritis is 2 mg once daily.

2. Baricitinib for COVID-19:

During the COVID-19 pandemic, baricitinib has been studied as a potential treatment for patients with severe illness. It is believed that baricitinib's anti-inflammatory properties may help reduce the exaggerated immune response seen in some COVID-19 patients. The recommended dosage of baricitinib for COVID-19 is 4 mg once daily for a maximum duration of 14 days.

3. Baricitinib for Alopecia Areata:

Alopecia areata is an autoimmune condition that results in hair loss, typically on the scalp but can affect other areas of the body as well. Baricitinib has shown promise in the treatment of alopecia areata by suppressing inflammatory pathways involved in the disease process. The recommended dosage of baricitinib for alopecia areata is 2 mg once daily.

It is important to note that the specific dosage and duration of treatment may vary depending on the individual's condition and the healthcare provider's recommendation. Patients should always consult their healthcare provider for personalized guidance.

Potential Side Effects of Baricitinib:

Like any medication, baricitinib can cause side effects, although not everyone experiences them. Some common side effects of baricitinib include upper respiratory tract infections, nausea, herpes zoster (shingles), and an increased risk of blood clotting. Serious side effects may include an increased risk of infections, liver enzyme elevations, and decreased neutrophil counts. Patients should be monitored closely for any signs of adverse effects while using baricitinib.

In conclusion, baricitinib is a medication used to treat rheumatoid arthritis, COVID-19, and alopecia areata. The recommended dosage varies depending on the condition being treated, and it is essential to follow the instructions provided by a healthcare professional. While baricitinib can be effective in managing these conditions, it is crucial to be aware of potential side effects and to communicate any concerns with a healthcare provider.